Effective treatment of tumors with strong β-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector

Cancer Research

Volumn 66, Issue 20, 2006, Pages 10127-10135

  Kuroda, Toshihiko ^a,b   Rabkin, Samuel D ^a   Martuza, Robert L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CPZN 3800 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; T CELL FACTOR PROTEIN; VIRUS VECTOR; WNT PROTEIN;

ARTICLE; CANCER CELL; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRON; PRIORITY JOURNAL; TANDEM REPEAT; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; BASE SEQUENCE; BETA CATENIN; CACO-2 CELLS; CARCINOMA, HEPATOCELLULAR; CERCOPITHECUS AETHIOPS; COLORECTAL NEOPLASMS; FEMALE; GENETIC VECTORS; HCT116 CELLS; HELA CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS (GENETICS); SIMPLEXVIRUS; TANDEM REPEAT SEQUENCES; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VERO CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33750541267     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2744     Document Type: Article

References (43)

1. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-51.
2. Pandur P, Lasche M, Eisenberg LM, Kuhl M. Wnt-II activation of a non-canonical Wnt signalling pathway is required for cardiogenesis. Nature 2002; 418:636-41.
3. Garcia-Castro MI, Marcelle C, Bronner-Fraser M. Ketodermal Wnt function as a neural crest inducer. Science 2002;297:848-51.
4. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005; 19:877-90.
5. Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of β-catenin-independent Wnt signaling. Dev Cell 2003;5:367-77.
6. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science 1996;272:1023-6.
7. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J Biol Chem 1997;272: 24735-8.
8. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
9. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-90.
10. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275: 1784-7.
11. Behrens J, Jerchow BA, Wurtele M, et al. Functional interaction of an axin homolog, conductin, with β-catenin. APC, and GSK3β. Science 1998;280:596-9.
12. Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P. Loss of β-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 1997;57:4624-30.
13. Nagase U, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993;2: 425-34.
14. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutattonai analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-1.
15. Jeng YM, Wu MZ, Mao TL, Chang MH, Hsu HC. Somatic mutations of β-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 2000;152:45-51.
16. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res 1999;59:269-73.
17. Wei Y, Fahre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA Activation of β-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000;19: 498-504.
18. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50.
19. Chen RH, McCormick F. Selective targeting to the hyperactive β-catenin/T-cell factor pathway in colon cancer cells. Cancer Res 2001;61:4445-9.
20. Brunori M, Malerba M, Kashiwazaki H, Iggo R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J Virol 2001;75:2857-65.
21. Kwong KY, Zou Y, Day CP, Hung MC. The suppression of colon cancer cell growth in nude mice by targeting β-catenin/TCF pathway. Oncogene 2002;21:8340-6.
22. Miyatake SI, Tani S, Feigenbaum F, et al. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 1999;6:564-72.
23. Yamamura H, Hashio M, Noguchi M, et al. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res 2001;61: 3969-77.
24. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 1997;71:5124-32.
25. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1: 938-43.
26. Post DE, Fulci G, Chiocca EA, Van Meir EG. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004;4:41-51.
27. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985;56:558-70.
28. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998;95:8847-51.
29. Rowan AJ, Bodmer WF. Introduction of a myc reporter tag to improve the quality of mutation detection using the protein truncation test. Hum Mutat 1997;9:172-6.
30. Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits." Proc Natl Acad Sci U S A 2000;97:3352-7.
31. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant J Virol 1988;62:196-205.
32. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992;89:5547-51.
33. Karpinski BA, Yang LH, Cacheris P, Morle GD, Leiden JM. The first intron of the 4F2 heavy-chain gene contains a transcriptional enhancer element that binds multiple nuclear proteins. Mol Cell Biol 1989;9: 2588-97.
34. Goodall J, Martinozzi S, Dexter TJ, et al. Brn-2 expression controls melanoma proliferation and is directly regulated by β-catenin. Mol Cell Biol 2004;24: 2915-22.
35. Lipinski KS, Djeha HA, Gawn J, et al. Optimization of a synthetic β-catenin-dependent promoter for tumor-specific cancer gene therapy. Mol Ther 2004;10: 150-61.
36. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotJde reductase-deficient herpes simplex viral mutant. Cancer Res 1994;54:3963-6.
37. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997; 275:1790-2.
38. Malerba M, Daeffler L, Rommelaere J, Iggo RD. Replicating parvoviruses that target colon cancer cells. J Virol 2003;77:6683-91.
39. Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 2005;65: 6882-90.
40. Rosin-Arbesfeld R, Cliffe A, Brabletz T, Bienz M. Nuclear export of the APC tumour suppressor controls β-catenin function in transcription. EMBO J 2003;22: 1101-13.
41. Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. Adenomatous polyposis coli (APC) differentially regulates β-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 2006;281: 17751-7.
42. Lipinski KS, Djeha AH, Ismail T, Mountain A, Young LS, Wrighton CJ. High-level, β-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol Ther 2001;4:365-71.
43. Coen DM, Goldstein DJ, Weller SK. Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob Agents Chemother 1989;33: 1395-9.